Minimizing Pregnancy/Postpartum Relapses: A Clinical Perspective

Volume 3, Issue 2

Minimizing Pregnancy/Postpartum Relapses: A Clinical Perspective

In this issue:

Disease reactivation during and after pregnancy is a challenge facing many women with MS and their clinicians. How can relapses be prevented? What are the benefits of pregnancy planning? What are the risk factors for postpartum MS reactivation? How can they be modified?

These are the questions Dr. Kristen Krysko from the University of California San Francisco addresses in this eMultipleSclerosis Review podcast.

Learning objectives:

Explain how pregnancy planning and management strategies can moderate the risk of MS relapse in pregnancy and postpartum.
Describe risk factors for postpartum MS relapses and the modifiable factors that can prevent them.

Author:

Kristen M Krysko, MD, MAS, FRCPC

Neuroimmunology Clinical Research Fellow
Weill Institute for Neurosciences, Department of Neurology
University of California San Francisco
San Francisco, CA

Guest Faculty Disclosures

Dr. Krysko has indicated that she has received partial support of fellowship by Biogen.

Unlabeled/Unapproved Uses

Dr. Krysko has disclosed that she will be discussing the use of disease-modifying therapies before/during pregnancy and while breastfeeding, with timing that differs from FDA product labels for drugs including glatiramer acetate, interferon-beta, natalizumab, rituximab, and ocrelizumab. Rituximab is not approved for use in MS.

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Guest Faculty Disclosures:

Dr. Krysko has indicated that she has received partial support of fellowship by Biogen.

Unlabeled/Unapproved Uses:

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: July 1, 2020
Expiration date: June 30, 2022

Start Issue